Life Sciences

AWS Digital Therapeutics Reference Architecture

Issue link:

Contents of this Issue


Page 0 of 2

For more information on Pharma and Biotech or other ways AWS can help your organization visit us at: © 2020, Amazon Web Services, Inc. or its Affiliates. All rights reserved. Building Secure & Scalable Digital Therapeutics on AWS Digital therapeutics (DTx) are evidence-based therapy interventions driven by high quality software and technology to help patients prevent, manage, or treat a broad range of conditions. DTx encompasses several subcategories: • Smart pills and connected inhalers to support pharmacological interventions by improving compliance and generating insights into patient behavior • Companion apps that leverage mobile technology to enhance the patient experience. • Standalone DTx to improve health outcomes independently of drug regimens. The Digital Therapeutics program at AWS is geared towards enabling life science organizations to develop, build, deploy, and optimize DTx programs using cloud-based technology. Below is a common HIPAA-eligible architecture pattern that AWS customers are using to develop DTx programs, harness data to improve patient engagement, and use analytics and machine learning to help predict patient health events. Amazon Web Services (AWS) offers HIPAA-eligible capabilities that benefit life science organizations through: $1B 40% US investment into DTx in 2018 1 annual growth of DTx 1 1 Scalability Build fast, low-latency patient applications Personalization Incorporate patient personalization for improved engagement and usage Data Security Comply with industry regulations and keep patient data secure New data Insights Use analytics and machine learning on diverse data sources

Articles in this issue

Links on this page

view archives of Life Sciences - AWS Digital Therapeutics Reference Architecture